NuCana (NASDAQ:NCNA) Stock Price Down 1.5% – What’s Next?

NuCana PLC Sponsored ADR (NASDAQ:NCNA)’s share price dropped 1.5% on Thursday . The company traded as low as $1.31 and last traded at $1.33. 31,744 shares traded hands during trading, a decline of 49% from the average daily volume of 62,270 shares. The stock had previously closed at $1.35.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of NuCana in a research note on Tuesday, April 21st. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, NuCana presently has an average rating of “Sell”.

NuCana Stock Down 1.1%

The firm’s fifty day moving average is $1.78 and its two-hundred day moving average is $2.16. The firm has a market cap of $5.47 million, a P/E ratio of -0.44 and a beta of 2.23.

NuCana (NASDAQ:NCNA) last issued its quarterly earnings data on Friday, May 15th. The company reported ($1.25) EPS for the quarter, topping the consensus estimate of ($2.64) by $1.39.

Institutional Trading of NuCana

A hedge fund recently raised its position in NuCana stock. FNY Investment Advisers LLC lifted its position in NuCana PLC Sponsored ADR (NASDAQ:NCNA) by 210.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,000 shares of the company’s stock after acquiring an additional 6,774 shares during the period. FNY Investment Advisers LLC owned 33.33% of NuCana worth $36,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 44.00% of the company’s stock.

NuCana Company Profile

NuCana plc, headquartered in Edinburgh, Scotland, is a clinical-stage biopharmaceutical company focused on developing novel anti-cancer therapies. The company leverages its proprietary ProTide platform to deliver enhanced nucleoside analogues designed to overcome resistance mechanisms commonly encountered in standard chemotherapy regimens. NuCana’s research and development efforts are aimed at improving safety and efficacy profiles for patients with a range of solid tumor indications.

At the core of NuCana’s pipeline is NUC-3373, a next-generation fluoropyrimidine analogue engineered to bypass degradation pathways and achieve more consistent intracellular exposure.